{"protocolSection": {"identificationModule": {"nctId": "NCT01074099", "orgStudyIdInfo": {"id": "Harvest 2009-1"}, "organization": {"fullName": "Harvest Technologies", "class": "INDUSTRY"}, "briefTitle": "Feasibility Study of BMAC Enhanced CABG", "officialTitle": "Feasibility Study of Autologous Concentrated Bone Marrow Nucleated Cell Therapy for Congestive Heart Failure Patients Undergoing Treatment With Coronary Artery Bypass Grafting(CABG) Surgery"}, "statusModule": {"statusVerifiedDate": "2014-08", "overallStatus": "TERMINATED", "whyStopped": "Pilot results in change to protocol, new study needed.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-02"}, "primaryCompletionDateStruct": {"date": "2013-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-02-01", "studyFirstSubmitQcDate": "2010-02-22", "studyFirstPostDateStruct": {"date": "2010-02-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2014-08-18", "resultsFirstSubmitQcDate": "2015-12-14", "resultsFirstPostDateStruct": {"date": "2016-01-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-12-14", "lastUpdatePostDateStruct": {"date": "2016-01-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Harvest Technologies", "class": "INDUSTRY"}, "collaborators": [{"name": "University of Utah", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2 centrifuge and have the concentrated nucleated cells injected into areas of ischemic myocardium", "detailedDescription": "Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2 centrifuge and have the concentrated nucleated cells injected into areas of ischemic myocardium. Control subjects will undergo CABG only"}, "conditionsModule": {"conditions": ["Congestive Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 5, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Control", "type": "ACTIVE_COMPARATOR", "description": "CABG only", "interventionNames": ["Procedure: CABG only"]}, {"label": "BMAC enhanced CABG", "type": "EXPERIMENTAL", "description": "Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery", "interventionNames": ["Biological: BMAC"]}], "interventions": [{"type": "BIOLOGICAL", "name": "BMAC", "description": "Injection of BMAC into ischemic myocardium during CABG", "armGroupLabels": ["BMAC enhanced CABG"]}, {"type": "PROCEDURE", "name": "CABG only", "description": "Control subjects will undergo CABG surgery without BMAC injection", "armGroupLabels": ["Control"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Cardiac Status (Classification)", "description": "A change in cardiac status as determined by the New York Heart Association (NYHA) or Canadian Cardiovascular Society (CCS) classification evaluation", "timeFrame": "Through 12 months post treatment"}, {"measure": "Safety", "description": "as measured by frequency and severity of adverse events", "timeFrame": "through 1 Year post tx"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age\\> 18 years and ability to understand the planned treatment.\n* Patients with ischemic congestive heart failure requiring by pass surgery\n* Congestive heart failure with ejection fraction \u2264 40%.\n* Serum bilirubin, SGOT and SGPT \u22642.5 time the upper level of normal.\n* Serum creatinine \\< 3.0 or no dialysis.\n* NYHA performance status \u2265 3.\n* Negative pregnancy test (in women with childbearing potential).\n* Subject has read and signed the IRB approved Informed Consent form\n* Hematocrit \u2265 28.0%, White Blood Cell count \u2264 14,000, Platelet count \u2265 50,000, Creatinine \u2264 3.0 mg / Dl, and/or no dialysis, INR \u2264 1.6 unless on Coumadin, or PTT \\<1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR\\<1.6 at the time of randomization/surgery\n\nExclusion Criteria:\n\n* Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.\n* History of Prior Radiation Exposure for oncological treatment.\n* History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.\n* History of abnormal Bleeding or Clotting.\n* History of Liver Cirrhosis.\n* Acute Myocardial Infarction \\< 4 weeks from treatment date.\n* Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemoccult unless follow-up studies reveal patient to be cancer free.\n* Active clinical infection being treated by antibiotics within one week of enrollment\n* Terminal renal failure with existing dependence on dialysis\n* Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.\n* Unable to have 250cc bone marrow harvested.\n* Medical risk that precludes anesthesia or ASA Class 5\n* History of ventricular arrhythmia if AICD is not present.\n* History of ventricular aneurysm.\n* Concurrent surgery such as CABG with valve surgery.\n* Minimally Invasive bypass surgery\n* Life expectancy \\<6 months due to concomitant illnesses\n* Treatment with immunosuppressant drugs (including Prednisone \\> 5 mg per day)\n* Patients undergoing urgent by pass surgical procedure\n* Patients with HGB A1C \\> 8.5%", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Amit Patel, MD", "affiliation": "University of Utah", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "The Methodist Hospital", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "University of Utah", "city": "Salt Lake City", "state": "Utah", "zip": "84112", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Control", "description": "CABG only\n\nCABG only: Control subjects will undergo CABG surgery without BMAC injection"}, {"id": "FG001", "title": "BMAC Enhanced CABG", "description": "Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery\n\nBMAC: Injection of BMAC into ischemic myocardium during CABG"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Control", "description": "CABG only\n\nCABG only: Control subjects will undergo CABG surgery without BMAC injection"}, {"id": "BG001", "title": "BMAC Enhanced CABG", "description": "Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery\n\nBMAC: Injection of BMAC into ischemic myocardium during CABG"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Cardiac Status (Classification)", "description": "A change in cardiac status as determined by the New York Heart Association (NYHA) or Canadian Cardiovascular Society (CCS) classification evaluation", "populationDescription": "Study was terminated after enrollment of only 5 patients. The data were not analyzed for efficacy.", "reportingStatus": "POSTED", "timeFrame": "Through 12 months post treatment", "groups": [{"id": "OG000", "title": "Control", "description": "CABG only\n\nCABG only: Control subjects will undergo CABG surgery without BMAC injection"}, {"id": "OG001", "title": "BMAC Enhanced CABG", "description": "Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery\n\nBMAC: Injection of BMAC into ischemic myocardium during CABG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Safety", "description": "as measured by frequency and severity of adverse events", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "through 1 Year post tx", "groups": [{"id": "OG000", "title": "Control", "description": "CABG only\n\nCABG only: Control subjects will undergo CABG surgery without BMAC injection"}, {"id": "OG001", "title": "BMAC Enhanced CABG", "description": "Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery\n\nBMAC: Injection of BMAC into ischemic myocardium during CABG"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "From time of treatment through 1 year / study termination", "eventGroups": [{"id": "EG000", "title": "Control", "description": "CABG only\n\nCABG only: Control subjects will undergo CABG surgery without BMAC injection", "seriousNumAffected": 0, "seriousNumAtRisk": 2, "otherNumAffected": 0, "otherNumAtRisk": 2}, {"id": "EG001", "title": "BMAC Enhanced CABG", "description": "Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery\n\nBMAC: Injection of BMAC into ischemic myocardium during CABG", "seriousNumAffected": 1, "seriousNumAtRisk": 3, "otherNumAffected": 0, "otherNumAtRisk": 3}], "seriousEvents": [{"term": "sustained ventricular tachycardia", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "patient had an episode during the investigational procedure when the injection into the heart occurred. recovered without sequelae", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 3}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The study was terminated early. Only 5 subjects were enrolled and they were followed for a year for safety data only. One efficacy data was collected."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Director of Clinical Operations", "organization": "Harvest Technologies", "email": "CLI2011communication@harvesttech.com", "phone": "508-732-7530"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Congestive Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}